Welcome international healthcare professionals

Welcome, this website is intended for Non-US international healthcare professionals with an interest in the treatment of lymphoma. By clicking the link below you are declaring and confirming that you are a healthcare professional.

You are here

Part 1: The science of targeting CD30

Prof. Illidge, Prof. Gisselbrecht, and Prof. Borchmann discussed the context and biology of CD30 and the rationale for CD30-targeting therapy. They also introduced the mechanism of action of brentuximab vedotin.

EHA webcast 01

Prof. Illidge, Prof. Gisselbrecht, and Prof. Borchmann discussed the context and biology of CD30 and the rationale for CD30-targeting therapy. They also introduced the mechanism of action of brentuximab vedotin.

You can download the slides here.

For best results, view this webcast in the latest version of your browser. If you are having problems watching this in an older browser, you can try updating your Flash Player.